30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q14 Revenue: Stryker

$2,305MM, +5% (U.S. $1,542MM, +7; ex-U.S. $763MM, +5%)

Reconstructive $999MM, +6% (U.S. +8%, ex-U.S. +3%)

  • Hips $318MM, +5% (U.S. +6%, ex-U.S. +4%)
  • Knees $348MM, +2% (U.S. +4%, ex-U.S. -2%)
  • Trauma/Extremities $288MM, +9% (U.S. +12%, ex-U.S. +7%; Foot/Ankle +34%)

Neurotechnology/Spine $420MM, +7% (U.S. +6%, ex-U.S. +9%)

  • Neurotechnology $243MM ,+12% (U.S. +11%, ex-U.S. +12%
  • Spine $177MM, +1% (U.S. +0.4%, ex-U.S. +4%)

MedSurg Equipment $886MM, +7% (U.S. +7%, ex-U.S. +7%)

  • Endoscopy $312MM, +8% (U.S. +6%, ex-U.S. +13%)

MedSurg includes patient handling and emergency medical equipment.

 

  • Completed acquisition of Pivot Medical and notes small CoAlign acquisition in 1Q
  • Hip and knee growth impacted by weather and disruption from MAKO acquisition
  • Will report MAKO hip and knee numbers in current segments, while capital will be reported in Other Recon
  • Moved all sports med implants previously reported under Recon to MedSurg (specifically, endoscopy); was ~$15MM per quarter
  • Initiated enrollment in trial of total knee application using MAKO technology, expecting to launch total knee in 2015